Galapagos: Banking On Steady Growth

|
About: Galapagos NV (GLPG), Includes: GILD
by: BioSci Capital Partners
This article is exclusive for subscribers.
Summary

This quarter, Galapagos inked a mega-deal with Gilead Sciences for the development and commercialization of filgotinib and other pipeline molecules.

With the strong phase 3 FINCH data, Gilead is submitting filgotinib for approval in the U.S. for rheumatoid arthritis by year-end. I expect approval in 2H2020.

The overall pipeline advancement is progressing at a rapid pace. As such, I anticipate more appreciation from this low-risk growth equity.

Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years? - Philip Fisher

If you've been following my work, you'd noticed